Acute Stroke Center Clinical Trials
BAYER STROKE STUDY
NEUROPROCTIVE TO BE GIVEN WITHIN 4.5 HOURS OF STROKE SYMPTOM ONSET (MAY ALSO HAVE t-PA)
Mechanism of Action:
Repinotan is a 5-HT1A receptor agonist which inhibits glutamate induced depolarization.
Study Objectives:
This is a phase IIb randomized, double blind, placebo controlled, parallel group, study to evaluate the efficacy, safety,
tolerability, and pharmacodynamic effects of a targeted exposure of IV Repinotan in patients with acute ischemic stroke.
ONO PHASE II-III STUDY
NEUROPROTECTIVE TO BE GIVEN WITHIN 6 HOURS OF STROKE SYMPTOM ONSET (MAY ALSO HAVE t-PA)
Mechanism of Action:
ONO-2506 is a novel neuroprotective agent that inhibits neuronal death and ameliorates neurological impairment in animal models
of experimentally induced cerebral infraction by inhibiting the abnormal activation of astrocytes and the resulting cytotoxicity.
Study Objectives:
The primary objective of this phase II-III, randomized, double blind, placebo-controlled, parallel group study is to compare
the effectiveness of 2 dose levels of ONO-2506 (4mg/kg/hr and 10 mg/kg/hour) to placebo, in patients with acute Ischemic stroke.
The secondary objectives of the study are to evaluate the safety and tolerability of ONO-2506. Other exploratory objectives
of the study are to assess the quality of life and to measure serum S-100ß protein levels.
NXY059 PHASE IIB/III ISCHEMIC STROKE STUDY
NEUROPROTECTIVE TO BE GIVEN WITHIN 6 HOURS OF STROKE SYMPTOM ONSET
Mechanism of Action:
NXY-059 is chemically a nitrone, which traps free radicals. The degree of brain damage caused by experimental brain ischemia
in the rat is reduced by NXY-059 even when treatment is started as late as 5 hours after onset of transient focal ischemia.
Study Objectives:
The primary objective is to demonstrate the efficacy of NXY-059 compares to placebo in subjects with acute ischemic stroke.
Other Stroke Trials
SWISS STUDY – SIBLINGS WITH ISCHEMIC STROKE
SUBJECTS (PROBANDS) WILL HAVE AN ISCHEMIC STROKE
Study Objectives:
- To test the hypothesis that there exist human chromosomal regions of interest associated with ischemic stroke. This hypothesis
will be tested by performing a genome-wide screen using DNA samples collected in this study from 300 concordant sibling pairs.
- To establish a secured cell bank of specimens from these sibpairs.
Coming Soon:
LOVENOX PHASE IV ISCHEMIC STROKE STUDY
ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN TO PREVENT VENOUS THROMBOEMBOLISM GIVEN WITHIN 48 HOURS AFTER ACUTE ISCHEMIC STROKE
Study Objectives:
To demonstrate superiority of enoxaparin 40 mg given sc once a day in the prevention of Venous Thromboembolism compared to
UFH 5000 Units sc given every 12 hours for 10 ± 4 days following acute ischemic stroke.
The PRoFESS STROKE STUDY
A STROKE SECONDARY PREVENTION STUDY OF AGGRENOX® VS. CLOPIDOGREL + ASPIRIN, WITH AND WITHOUT MICARDIS®
Study Objectives:
To investigate which of four treatment regimens utilizing commonly prescribed medications is best in preventing recurrent
stroke in patients who have already suffered as ischemic stroke. This study will include over 15,500 patients in at least
24 countries and last approximately four years.
Study Coordinator: Lisa Bowman, RN, CRNP: 215-955-9506
